Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.59 |
| ▸ | ACACA | Q13085 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22819360 | 1.00 | ACACB (0.59) | ACACBACACAFFAR1FFAR4GPR84 | |
| SCHEMBL10264139 | 0.97 | ACACB (0.56) | ACACBACACAFFAR1FFAR4GPR84 | |
| SCHEMBL14293914 | 0.92 | ACACB (0.48) | ACACBACACAFFAR1FFAR4GPR84 | |
| SCHEMBL12092765 | 0.91 | ACACB (0.52) | ACACBACACAFFAR1FFAR4GPR84 | |
| SCHEMBL8897109 | 0.91 | FFAR1 (0.52) | ACACBACACAFFAR1FFAR4GPR84 | |
| SCHEMBL25479048 | 0.91 | ACACB (0.52) | ACACBACACAFFAR1FFAR4GPR84 | |
| SCHEMBL8895607 | 0.91 | FFAR1 (0.52) | ACACBACACAFFAR1FFAR4GPR84 | |
| SCHEMBL8897199 | 0.91 | ACACB (0.52) | ACACBACACAFFAR1FFAR4GPR84 | |
| SCHEMBL8897706 | 0.91 | ACACB (0.52) | ACACBACACAFFAR1FFAR4GPR84 | |
| SCHEMBL30483471 | 0.91 | ACACB (0.52) | ACACBACACAFFAR1FFAR4GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113735701-B | Preparation method of 8-hydroxy-2,2,14,14-tetramethyl pentadecane diacid | 新发药业有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-115504914-B | Preparation method of bevacizidine acid intermediate | 武汉武药科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117623923-A | Synthesis method of bevacizidine acid intermediate compound | 安徽艾立德制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117551009-A | Synthesis method of bevacizidine acid intermediate | 武汉武药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-116924886-A | Synthesis method of 8-oxo-2,2,14,14-tetramethyl pentadecanedioic acid | 武汉武药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-113735701-B | Preparation method of 8-hydroxy-2,2,14,14-tetramethyl pentadecane diacid | 新发药业有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-113735701-B | Preparation method of 8-hydroxy-2,2,14,14-tetramethyl pentadecane diacid | 新发药业有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-113735701-B | Preparation method of 8-hydroxy-2,2,14,14-tetramethyl pentadecane diacid | 新发药业有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116120163-A | Synthesis method of bevacizidine acid and intermediate thereof | 安徽艾立德制药有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-109721486-A | A kind of synthetic method of 8- hydroxyl -2,2,14,14- tetramethyl-pentacosandioic acid | 鲁南制药集团股份有限公司 | 2019-05-07 | — | — | CN | disclosed |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9000041-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130289117-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289117-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2011-01-06 | — | — | US | disclosed |
| US-7335799-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289117-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR1 205/4885 |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR1 205/4885 |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.